I-Mab Delivers Mid-Year 2023 Results

Press Releases

2023.09.05

I-Mab Announces Upcoming Participation at September Conferences

I-Mab announced participation in investor conferences in September 2023.

2023.08.17

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

The Company today announced its financial results for the 6 months ended June 30, 2023, and provided key business updates.

2023.08.08

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

I-Mab will host an investor call to report interim earnings on Aug 17.

Partner News

2023.05.25

HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy

2023.04.11

HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy

2021.07.09

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

Media Reports

2022.02.03

Endpoints: I-Mab expands manufacturing for multiple myeloma antibody; Granules issued ‘minor observations’ after inspection

Read at Endpoints

2021.07.09

FierceBiotech: I-Mab boards popular mRNA train with 2 biotech collaborations

Read at FierceBiotech

2021.05.19

2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody

Read at Endpoints